Cytosorbents (NASDAQ:CTSO) Stock Passes Above 200 Day Moving Average – Should You Sell?

Cytosorbents Co. (NASDAQ:CTSO) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com started coverage on shares of Cytosorbents in a report on Tuesday. They set a “hold” rating for the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Up 2.7 %

The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.05. The company has a market cap of $61.79 million, a price-to-earnings ratio of -3.14 and a beta of 0.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp raised its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Skylands Capital LLC raised its stake in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after buying an additional 26,195 shares during the period. Geode Capital Management LLC boosted its stake in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Cytosorbents during the 4th quarter worth approximately $30,000. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.